Teychenne P F, Pfeiffer R, Bern S M, Calne D B
Neurology. 1977 Dec;27(12):1140-3. doi: 10.1212/wnl.27.12.1140.
Studies on rats with unilateral nigral lesions suggest that a new ergoline, CF 25-397, is a dopaminergic agonist that might improve parkinsonism. CF 25-397 induces less stereotyped behavior than other dopaminergic agents in rats, and might therefore cause less dyskinesia than levodopa in man. We investigated the clinical actions of CF 25-397 in nine patients. During treatment, severe deterioration resulted in hypokinesia and rigidity; five patients showed marked dysphagia and dysphonia. There was statistically significant deterioration in four timed tests. Mild improvement, not statistically significant, was noted in tremor. These results indicate that clinical implication of the response to potential therapeutic agents in rodent models of parkinsonism must be interpreted with caution.
对单侧黑质损伤大鼠的研究表明，一种新的麦角灵CF 25 - 397是一种多巴胺能激动剂，可能改善帕金森病。与其他多巴胺能药物相比，CF 25 - 397在大鼠中诱发的刻板行为较少，因此在人类中可能比左旋多巴引起的运动障碍更少。我们研究了CF 25 - 397对9名患者的临床作用。在治疗期间，严重恶化导致运动徐缓和僵硬；5名患者出现明显的吞咽困难和发音困难。在四项定时测试中出现了具有统计学意义的恶化。在震颤方面有轻微改善，但无统计学意义。这些结果表明，在帕金森病啮齿动物模型中对潜在治疗药物反应的临床意义必须谨慎解读。
